Get 40% Off
🚨 Volatile Markets? Find Hidden Gems for Serious OutperformanceFind Stocks Now

Former U.S. Treasury secretaries back drugs, climate, tax bill

Published 08/03/2022, 10:52 AM
Updated 08/03/2022, 12:11 PM
© Reuters. FILE PHOTO:  Former U.S. Treasury Secretary Henry Paulson speaks at the 2019 New Economy Forum in Beijing, China November 21, 2019. REUTERS/Jason Lee

By David Lawder

WASHINGTON (Reuters) - Five former U.S. Treasury secretaries - four Democrats and one Republican -- on Wednesday voiced support for a proposed $430 billion drugs, energy and tax bill, saying that it would reduce costs for middle-class families.

The statement from former secretaries Robert Rubin, Larry Summers, Jacob Lew, Tim Geithner and Henry Paulson echo a letter sent by current Treasury Secretary Janet Yellen to congressional leaders on Tuesday that the bill would not raise taxes for Americans earning less than $400,000.

The statement excluded Steven Mnuchin, the most recent former secretary, who served in former president Donald Trump's Republican administration. Paulson, the lone Republican in the group, has championed environmental causes, including transitioning to clean energy.

Republicans have argued that the bill would break President Biden's pledge not to raise taxes on that level because of a Joint Committee on Taxation analysis of distributional effects of income and taxes from the legislation, known as the "Inflation Reduction Act of 2022".

The JCT analysis shows that higher taxes paid by corporations would indirectly raise the effective tax burdens of Americans with incomes of $200,000 or less by $16.7 billion in 2023, through income reduction effects.

The former Treasury secretaries, in a statement issued by Summers' Harvard University office, said the bill was "financed by prudent tax policy that will collect more from top earners and large corporations.

"Taxes due or paid will not increase for any family making less than $400,000/year. And the extra taxes levied on corporations do not reflect increases in the corporate tax rate, but rather the reclaiming of revenue lost to tax avoidance and provisions benefiting the most affluent," they said.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

The secretaries also said the JCT analysis selectively presented distributional effects of the bill, but neglected to show its benefits to middle-class families from reduced prescription drug prices to more affordable energy.

"This legislation will help increase American competitiveness, address our climate crisis, lower costs for families, and fight inflation — and should be passed immediately by Congress," the former secretaries said.

Summers last year was critical of the Biden administration's $1.9 trillion American Rescue Plan COVID-19 relief package, arguing that it was excessive and would stoke persistent inflation.

The proposed legislation would provide new federal funding for a significant reduction in U.S. carbon dioxide emissions that contribute to climate change and allow Medicare, the federal health insurance program for the elderly and disabled, to negotiate lower pharmaceutical prices.

The bill would be financed by a new 15% domestic corporate minimum tax large firms with more than $1 billion in book income, while closing some credits and deductions benefiting wealthy Americans.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.